CLINICAL_Word Swarm Large

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for patients with Stage IB, II, or IIIA non-small cell lung cancer. The Genentech ML39236 study will open in early April.

The Genentech ML395236 study is a phase II, open-label trial that will investigate atezolizumab as therapy before and after surgery in patients with resectable and untreated non- small cell lung cancer.

Read more: http://lcfamerica.org/wp-content/uploads/2017/04/Issue-51-March-TOTR-Patient-Newsletter.pdf